Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Exemestane (Primary) ; Cyclophosphamide; Docetaxel
- Indications Early breast cancer
- Focus Therapeutic Use
- 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 11 Feb 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 16 Nov 2014 Planned number of patients changed from 70 to 85, according to the ClinicalTrials.gov record.